Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update

Daniel P O’Brien, Grant Jenkin, John Buntine, Christina M Steffen, Anthony McDonald, Simon Horne, N Deborah Friedman, Eugene Athan, Andrew Hughes, Peter P Callan and Paul D R Johnson
Med J Aust 2014; 200 (5): 267-270. || doi: 10.5694/mja13.11331


  • Guidelines reflecting contemporary clinical practice in the management of Buruli ulcer (Mycobacterium ulcerans infection) in Australia were published in 2007.

  • Management has continued to evolve, as new evidence has become available from randomised trials, case series and increasing clinical experience with oral antibiotic therapy.

  • Therefore, guidelines on the diagnosis, treatment and prevention of Buruli ulcer in Australia have been updated. They include guidance on the new role of antibiotics as first-line therapy; the shortened duration of antibiotic treatment and the use of all-oral antibiotic regimens; the continued importance, timing and role of surgery; the recognition and management of paradoxical reactions during antibiotic treatment; and updates on the prevention of disease.

Please login with your free MJA account to view this article in full

  • Daniel P O’Brien1,2
  • Grant Jenkin3
  • John Buntine4
  • Christina M Steffen5
  • Anthony McDonald1
  • Simon Horne6
  • N Deborah Friedman1
  • Eugene Athan1
  • Andrew Hughes1
  • Peter P Callan7
  • Paul D R Johnson8,9

  • 1 Barwon Health, Geelong, VIC.
  • 2 Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC.
  • 3 Southern Health, Melbourne, VIC.
  • 4 Cornell Specialist Centre, Melbourne, VIC.
  • 5 Cairns Base Hospital, Cairns, QLD.
  • 6 Point Lonsdale Medical Group, Point Lonsdale, VIC.
  • 7 St John of God Hospital, Geelong, VIC.
  • 8 Austin Health, Melbourne, VIC.
  • 9 WHO Collaborating Centre for Mycobacterium ulcerans (Western Pacific Region), Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC.

Competing interests:

No relevant disclosures.

  • 1. Johnson PD, Stinear T, Small PL, et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLOS Med 2005; 2: e108.
  • 2. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283: 854-857.
  • 3. Boyd SC, Athan E, Friedman ND, et al. Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med J Aust 2012; 196: 341-344. <MJA full text>
  • 4. Jenkin GA, Smith M, Fairley M, Johnson PD. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 2002; 176: 180-181. <MJA full text>
  • 5. Steffen CM, Smith M, McBride WJ. Mycobacterium ulcerans infection in North Queensland: the ‘Daintree ulcer’. ANZ J Surg 2010; 80: 732-736.
  • 6. Francis G, Whitby M, Woods M. Mycobacterium ulcerans infection: a rediscovered focus in the Capricorn Coast region of central Queensland. Med J Aust 2006; 185: 179-180. <MJA full text>
  • 7. Quinn JV, Crotty JM. Mycobacterium ulcerans infections in the Northern Territory. Med J Aust 1963; 2: 317-319.
  • 8. Johnson PD, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007; 186: 64-68. <MJA full text>
  • 9. O’Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186: 58-61. <MJA full text>
  • 10. Bentoucha A, Robert J, Dega H, et al. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2001; 45: 3109-3112.
  • 11. Ji B, Chauffour A, Robert J, et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007; 51: 3737-3739.
  • 12. Ji B, Lefrançois S, Robert J, et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006; 50: 1921-1926.
  • 13. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49: 3182-3186.
  • 14. Gordon CL, Buntine JA, Hayman JA, et al. All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLOS Negl Trop Dis 2010; 4: e770.
  • 15. O’Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLOS Negl Trop Dis 2012; 6: e1473.
  • 16. Friedman ND, Athan E, Hughes AJ, et al. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLOS Negl Trop Dis 2013; 7: e2315.
  • 17. Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997; 35: 1696-1700.
  • 18. Yeboah-Manu D, Danso E, Ampah K, et al. Isolation of Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin Microbiol 2011; 49: 1997-1999.
  • 19. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 664-672.
  • 20. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007; 51: 4029-4035.
  • 21. Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010; 54: 3678-3685.
  • 22. Chauty A, Ardant MF, Marsollier L, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52: 94-96.
  • 23. World Health Organization. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. Geneva: WHO, 2012.
  • 24. Thangaraj HS, Adjei O, Allen BW, et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000; 45: 231-233.
  • 25. Saito H, Ishii N. Antibacterial activities of new fluoroquinolones against Mycobacterium ulcerans. J Antimicrob Chemother 2001; 47 Suppl 1: 30.
  • 26. O’Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. J Med Case Rep 2008; 2: 123.
  • 27. Yoshida K, Yabe K, Nishida S, et al. Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. J Vet Pharmacol Ther 1998; 21: 128-132.
  • 28. Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002; 21: 1136-1141.
  • 29. Simpson C, O’Brien DP, McDonald A, Callan P. Mycobacterium ulcerans infection: evolution in clinical management. ANZ J Surg 2013; 83: 523-526.
  • 30. O’Brien DP, Walton A, Hughes AJ, et al. Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort. Med J Aust 2013; 198: 436-439. <MJA full text>
  • 31. Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012; 54: 519-526.
  • 32. O’Brien DP, Robson M, Friedman ND, et al. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis 2013; 13: 416.
  • 33. Ruf MT, Chauty A, Adeye A, et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLOS Negl Trop Dis 2011; 5: e1252.
  • 34. O’Brien DP, Robson ME, Callan PP, McDonald AH. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009; 191: 564-566. <MJA full text>
  • 35. Friedman ND, McDonald AH, Robson ME, O’Brien DP. Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLOS Negl Trop Dis 2012; 6: e1767.
  • 36. Trevillyan JM, Johnson PD. Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust 2013; 198: 443-444. <MJA full text>
  • 37. Junghanss T, Um Boock A, Vogel M, et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLOS Negl Trop Dis 2009; 3: e380.
  • 38. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13: 1653-1660.
  • 39. Quek TY, Henry MJ, Pasco JA, et al. Mycobacterium ulcerans infection: factors influencing diagnostic delay. Med J Aust 2007; 187: 561-563. <MJA full text>
  • 40. Johnson PD, Lavender CJ. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis 2009; 15: 614-615.
  • 41. Fyfe JA, Lavender CJ, Handasyde KA, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLOS Negl Trop Dis 2010; 4: e791.
  • 42. Pouillot R, Matias G, Wondje CM, et al. Risk factors for buruli ulcer: a case control study in Cameroon. PLOS Negl Trop Dis 2007; 1: e101.
  • 43. Landier J, Boisier P, Fotso Piam F, et al. Adequate wound care and use of bed nets as protective factors against Buruli ulcer: results from a case control study in Cameroon. PLOS Negl Trop Dis 2011; 5: e1392.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

access_time 02:27, 3 April 2014

<p>As a GP at the centre of the daintree ulcer zone &nbsp;we welcome the new guidelines on antimicrobial therapy. Can i request that the authors push for authority PBS listing for the required medication as otherwise the cost is somewhat prohibitive for many of my clients</p>

Competing Interests:

Responses are now closed for this article.